louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00700960: Observational Study Describing Conditions for Administering Slow-acting Insulin Analogue With Oral Antidiabetic Agents in Type 2 Diabetes on Blood Glucose Control
Official title: Observational Study on Efficacy on Glycaemic Control of Slow-acting Insulin Analogue in Type 2 Diabetes
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2008-06-19
Enrollment: 2745
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with type 2 diabetes

Brief summary: This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood glucose control in type 2 diabetes.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes
* HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level
* Patient agreeing to take part in the study and capable of completing a self-questionnaire.

Exclusion Criteria:

* Hypersensitivity to insulin or to one of the excipients
* Treatment with insulin for at least 6 months
* Participant in a clinical trial for diabetes on entry into the observational study

Primary outcomes:
measure: HbA1c
timeFrame: After 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Paris La Défense
country: France
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Verges B, Brun JM, Tawil C, Alexandre B, Kerlan V. Strategies for insulin initiation: insights from the French LIGHT observational study. Diabetes Metab Res Rev. 2012 Jan;28(1):97-105. doi: 10.1002/dmrr.1288.
Clinical trial NCT04157660: Effect of Short-term Oxygen During CPET in HFpEF
Official title: Effect of Short-term Ambulatory Oxygen Therapy on Cardiopulmonary Exercise Capacity (CPET) in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Failure, Diastolic (HFpEF)
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2019-11-08
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: In a randomized, sham-controlled crossover trial the investigators will test whether supplemental oxygen given during cardiopulmonary exercise testing will improve exercise performance and physiological parameters in patients with heart failure with preserved ejection fraction.


Eligibility criteria: Inclusion Criteria:

* HFpEF, stable medication for at least 4 weeks.

Exclusion Criteria:

* instable status, pregnancy, clinically relevant concomitant diseases, inability to follow the study procedures

Primary outcomes:
measure: Work Rate (Watt)
timeFrame: 1 day
measure: Endurance Time (s)
timeFrame: 1 day
Secondary outcomes:
measure: Peak Oxygen uptake (VO2 max)
timeFrame: 1 day
measure: Respiratory Exchange Ratio (RER)
timeFrame: 1 day
measure: Changes in arterial blood parameters (pH)
timeFrame: 1 day
measure: Changes in arterial blood parameters (PaO2)
timeFrame: 1 day
measure: Changes in arterial blood parameters (PaCO2)
timeFrame: 1 day
measure: Changes in arterial blood parameters (Lactat)
timeFrame: 1 day
measure: Changes in arterial blood parameters (Bicarbonate)
timeFrame: 1 day
measure: muscle tissue oxygen
timeFrame: 1 day
measure: cerebral tissue oxygen
timeFrame: 1 day
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: University Hospital Zurich, Division of Pneumology
Study officials:
affiliation: University Hospital Zurich, Division of Pneumology
name: Silvia Ulrich Somaini, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Muller J, Lichtblau M, Saxer S, Calendo LR, Carta AF, Schneider SR, Berlier C, Furian M, Bloch KE, Schwarz EI, Ulrich S. Effect of Breathing Oxygen-Enriched Air on Exercise Performance in Patients With Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction: A Randomized, Placebo-Controlled, Crossover Trial. Front Med (Lausanne). 2021 Jul 28;8:692029. doi: 10.3389/fmed.2021.692029. eCollection 2021.
Clinical trial NCT04130360: A Trial of an Online Problem-solving Intervention for Aggression
Official title: A Randomized Controlled Trial of an Online Problem-solving Intervention to Reduce Aggression Among Youth
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Aggression
Keywords: problem-solving
youth
brief intervention
online intervention
young people
aggressive behaviour
Lead sponsor: University of Sheffield
Sponsor class: OTHER
Collaborators: name: University of Manchester
First posted: 2019-10-17
Enrollment: 908
Sex: ALL
Minimum age (years): 18
Maximum age (years): 21
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Intervention and control group. Participants are randomised to one of them.
Primary purpose: BASIC_SCIENCE

Brief summary: Aggressive behaviour among adolescents is a social problem that can be reduced by social problem-solving interventions. However, these interventions usually include more than one technique, and the specific techniques that are effective in reducing and preventing aggression remain to be identified. Therefore, the main aim of this study is to test whether the instruction and practice of problem-solving on their own are effective in changing aggressive behaviour among adolescents.

As the intervention in this trial is aimed at the general population, it will be delivered online. The rapid growth in the use of the Internet among young people provides an opportunity to deliver interventions universally in a cheap and efficient way.

Problem-solving skills are fundamental to effective behaviour change. Therefore, problem-solving skills will be measured to assess whether they mediate the effect of the intervention on aggressive behaviour.

Finally, young people with callous-unemotional traits are less likely to change their problematic behaviour such as aggression after an intervention. Therefore, Callous-Unemotional traits will be measured to assess if they act as a moderator of effectiveness.

It is expected that participants randomised to the intervention improve their problem-solving skills and consequentially, reduce their aggressive behaviours. In addition, participants with lower callous-unemotional traits are expected to have a greater change.


Eligibility criteria: Inclusion Criteria:

* Living in the UK
* Fluent in English

Primary outcomes:
measure: Aggression (trait)
timeFrame: 1 month
measure: Aggression (frequency)
timeFrame: 1 month
Secondary outcomes:
measure: Problem-solving skills
timeFrame: 1 month
measure: Problem-solving self-efficacy
timeFrame: 1 month
Other outcomes:
Locations:
city: Sheffield
country: United Kingdom
facility: University of Sheffield
state: South Yorkshire
Study officials:
affiliation: University of Sheffield
name: Laura Castillo-Eito
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01001260: PGD2 Formation in Vascular Injury
Official title: Biosynthesis of PGD2 in Vascular Injury
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Coronary Artery Disease
Acute Coronary Syndrome
Stable Angina
Keywords: Prostaglandins
vascular injury
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
First posted: 2009-10-26
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients scheduled to have PTCA

Brief summary: To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.

Detailed description: A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans

B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.

Eligibility criteria: Inclusion Criteria:

* Patients with existing CAD admitted for elective PTCA:

  1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or
  2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or
  3. No aspirin therapy at all
* Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA
* Patients with stable angina or positive stress tests scheduled for a cardiac catheterization

Exclusion Criteria:

* History of unstable diabetes (hgb A1c\>8 or FBS\> 200)
* Uncontrolled hypertension (SBP \> 180, DBP \>100)
* History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject.
* Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA

Primary outcomes:
measure: The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite.
timeFrame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.
Secondary outcomes:
measure: Whether aspirin could blunt the increment of PGD2 if there is.
timeFrame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.
Other outcomes:
Locations:
Study officials:
affiliation: University of Pennsylvania
name: Garret FitzGerald, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Pennsylvania
name: Wenliang Song, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01794260: Efficacy and Safety of Topical Essential Oil Extracted From Zingiber Cassumunar Rokb in Osteoarthritis
Official title: Efficacy and Safety of Topical Preparation of Essential Oil Extracted From Zingiber Cassumunar Rokb in Patients With Osteoarthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Osteoarthritis
Keywords: Osteoarthritis
Moderate ot severe pain
ZINGIBER CASSUMUNAR ROXB
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2013-02-18
Enrollment: 100
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objectives of this study are to assess short term efficacy and safety of of topical preparation of essential oil extracted from ZINGIBER CASSUMUNAR ROXB in patients suffering from osteoarthritic pain


Eligibility criteria: Inclusion Criteria:

* Diagnosis: osteoarthritis of the knee at least on side with standard radiologic method within 6 weeks (Kellgren-Lawrence radiographic grading scale at least 1)
* Pain visual analog scale at rest at least 40 mm
* No previous analgesic treatment or receiving stable dose of analgesic drugs at least 2 weeks. If previously treated with antidepressants, glucosamine, chondroitin or diacerein, dosage should be stable for at least 3 months.
* Agree to attain non-pharmacologic treatment as prior to participate the study

Exclusion Criteria:

* having an open wound or abnormal skin at site of application
* having diagnose with other chronic arthritis such as rheumatoid arthritis
* history of allergy to the extraction of Zingiber cassumunar Roxb
* pregnancy or breastfeeding

Primary outcomes:
measure: Change from baseline of The WOMAC (Western Ontario and McMaster Universities) index
timeFrame: week 8
Secondary outcomes:
measure: Change from baseline of Pain visual analog scale (PVAS)
timeFrame: week 8
measure: Change from baseline of Global assessment of disease status (GADS)
timeFrame: week 8
measure: Clinical global impression of change (CGIC)
timeFrame: Week 8
measure: Patient global impression of change (PGIC)
timeFrame: Week 8
measure: Adverse events
timeFrame: Week 8
Other outcomes:
Locations:
city: Ongkarak
country: Thailand
facility: Faculty of Medicine, Srinakharinwirot University
state: Nakhonnayok
Study officials:
affiliation: Department of Pharmacology, Faculty of Pharmacy, Mahidol University 447 Sri-Ayudhya Rd., Rajthevee, Bangkok 10400, Thailand
name: Chuthamanee Suthisisang, Ph.D.
role: STUDY_DIRECTOR
affiliation: Faculty of Pharmacy, Srinakharinwirot University
name: Suwimon Yeephu, M.Sc.
role: PRINCIPAL_INVESTIGATOR
affiliation: Mahidol University
name: Chuthamanee Suthisisant, Ph.D
role: STUDY_CHAIR
References:
Clinical trial NCT00858260: Arnogene: A Phosphocalcic Study in Dialysis
Official title: Genetic Determinants of Phosphocalcic Metabolism in Hemodialysis Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Dialysis
Keywords: Klotho
calcium
phosphate
parathormone
survival
dialysis
Adult patients undergoing maintenance dialysis since at leat three months
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2009-03-09
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients undergoing maintenance dialysis since at leat three months

Brief summary: Searching for high morbi-mortality risk Klotho variants in dialysis patients


Eligibility criteria: Inclusion Criteria:

* Every adult \> 18 years old and treated by dialysis in centers located in the Rhone Alpes area in France.

Primary outcomes:
measure: Assessing morbi-mortality based on Klotho variants
Secondary outcomes:
measure: Survival and serum phosphocalcic parameters
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hôpital Edouard Herriot
Study officials:
affiliation: Hospices Civils de Lyon
name: FOUQUE Denis, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH Annonay
name: LEGRAND Eric, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH Bourgoin Jallieu
name: KAARASLAN Huseyin, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH Chalon/saône
name: ABOKASEM Ayman, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH Sallanches
name: LATAILLADE Claire Dominique, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre Dialyse eaux claires
name: KUENTZ François, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CHU Grenoble - La Tronche
name: HACHACHE Toufic, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hospices Civils de Lyon
name: LEITIENNE Philippe, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: AURAL - Lyon
name: ARKOUCHE Walid, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH MACON
name: HEYANI Ahmed, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH Villefranche/saône
name: HANNOUN Jacques, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Clinique du Tonkin VILLEURBANNE
name: COMBARNOUS François, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: AGDUC - Montélimar
name: MAUREAUGANDRY Xavier, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: CH ROMANS/ISERE
name: SIRAJEDINE Mohamed, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Centre du Rein - Tassin la demi lune
name: JEAN Ahmed, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Calydial - CH Viennes
name: DENICOLA Cora, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Marcais C, Maucort-Boulch D, Drai J, Dantony E, Carlier MC, Blond E, Genet L, Kuentz F, Lataillade D, Legrand E, Moreau-Gaudry X, Jean G, Fouque D; ARNOGENE Project. Circulating Klotho Associates With Cardiovascular Morbidity and Mortality During Hemodialysis. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3154-3161. doi: 10.1210/jc.2017-00104.
Clinical trial NCT05107960: A Study of Azilsartan in Children from 6 to Less Than 16 Years Old with High Blood Pressure
Official title: Special Drug Use Surveillance; AZILVA Tablets and AZILVA Granules 1% in Pediatric Use
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hypertension
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2021-11-04
Enrollment: 5
Sex: ALL
Minimum age (years): 6
Maximum age (years): 15
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Children with hypertension aged 6 years or older and less than 16 years will be included in the survey.

Brief summary: The main aim of this study is to check for side effects from treatment with azilsartan and how well azilsartan controls blood pressure in children from 6 to less than 16 years old with high blood pressure.

The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with high blood pressure will take azilsartan tablets or azilsartan granules once a day according to their clinic's standard practice. The study doctors will check for side effects from azilsartan for up to 12 months after treatment starts.


Eligibility criteria: Inclusion Criteria

1. Participants aged 6 years or older and less than 16 years
2. Participants with hypertension

Exclusion Criteria Participants with contraindications to azilsartan.

Primary outcomes:
measure: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)
timeFrame: Up to 12 Months
measure: Number of Participants Who Experienced at Least One Serious Adverse Event (SAE)
timeFrame: Up to 12 Months
measure: Actual Measured Value of Blood Pressure
timeFrame: Baseline, up to Months 12
measure: Changes from Baseline in Blood Pressure
timeFrame: Baseline, up to Months 12
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Takeda selected site
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT01588860: Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma
Official title: Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Biliary Tract Adenocarcinoma
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2012-05-01
Enrollment: 100
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The patients diagnosed as biliary tact adenocarcinoma.

Brief summary: Cholangiocarcinoma is a fatal malignant neoplasm originating from biliary tracts and constitutes about 5-10% of primary liver cancers, characterized by a poor prognosis. High prevalence in southeast and eastern Asia has been observed. At present, the cellular and molecular mechanisms leading to oncogenesis of cholangiocarcinoma remain unclear.

The RAS gene product has a key role in controlling cell growth and differentiation through its intrinsic GTPase activity. Point mutations that activate the RAS protein and its downstream cascade have been observed in human tumors. Both KRAS and BRAF are members of the RAS-RAF-MEK-ERK-MAP kinase pathway which mediates cellular response to growth signals. Somatic KRAS mutations are found at high rates in leukemia, colon cancer, pancreatic cancer and lung cancer. Studies from European and Japanese groups have recently described that activating KRAS/ BRAF mutations may play a role in the carcinogenesis of cholangiocarcinoma of the biliary tracts, but our preliminary data demonstrated low frequency of KRAS and BRAF mutation in the same tumor as well as the results from Thailand. In this study, the investigators hypothesize copy number changes rather than genetic mutation of either KRAS or BRAF genes may be the key findings of Taiwanese cases of the adenocarcinoma from the biliary tracts.


Eligibility criteria: Inclusion Criteria:

* The patients diagnosed as biliary tact adenocarcinoma.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Department of Pathology, Far Eastern Memorial Hospital and National Taiwan University Hospital
Study officials:
References:
Clinical trial NCT03988894: mDASHNa-CC APP to Support a Healthy Diet and Hypertension Control for Chinese Canadian Seniors
Official title: Design, Usability Testing, and Feasibility Testing of a Smartphone App (mDASHNa-CC) to Support Healthy Diet and Hypertension Control for Chinese Canadian Seniors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Hypertension
Diet, Healthy
Lead sponsor: University of Toronto
Sponsor class: OTHER
First posted: 2019-06-18
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A pilot two-group (1:1) randomized controlled trial with a sample size of 60 (block of 20) in a Chinese Canadian community in the Greater Toronto Area, Ontario, Canada.
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of this proposed study is to translate the Dietary Approach to Stop Hypertension with Sodium (Na) Reduction for Chinese Canadian (DASHNa-CC), a classroom-based antihypertensive dietary educational intervention, to an innovative smartphone app (mDASHNa-CC) to enable Chinese Canadian seniors' access to this antihypertensive dietary intervention anytime, regardless of where they are.


Eligibility criteria: Inclusion Criteria:

* have a systolic blood pressure higher than 140 mmHg, or a diastolic blood pressure higher than 90mmHg, or are on antihypertensive medications, based on pre-intervention baseline assessment
* are able to understand (listen) and speak in Mandarin or Cantonese, read and write in Chinese
* have access to a smartphone

Exclusion Criteria:

* have special dietary requirements
* are a household member of another mDASHNa-CC participant
* plan to leave the area prior to the anticipated end of study

Primary outcomes:
measure: change of systolic Blood Pressure from baseline to eight weeks after randomization
timeFrame: eight weeks after randomization
measure: change of diastolic Blood Pressure from baseline to eight weeks after randomization
timeFrame: eight weeks after randomization
measure: change of body weight from baseline to eight weeks after randomization
timeFrame: eight weeks after randomization
measure: change of waist circumference from baseline to eight weeks after randomization
timeFrame: eight weeks after randomization
measure: change of Health-related Quality of Life from baseline to eight weeks after randomization
timeFrame: eight weeks after randomization
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Zou P, Stinson J, Parry M, Dennis CL, Yang Y, Lu Z. A Smartphone App (mDASHNa-CC) to Support Healthy Diet and Hypertension Control for Chinese Canadian Seniors: Protocol for Design, Usability and Feasibility Testing. JMIR Res Protoc. 2020 Apr 2;9(4):e15545. doi: 10.2196/15545.